Last Price
0.673
Today's Change
-0.007 (1.02%)
Day's Change
0.662 - 0.716
Trading Volume
2,673,445
Market Cap
1 Million
Shares Outstanding
2 Million
Avg Volume
3,278,970
Avg Price (50 Days)
3.77
Avg Price (200 Days)
13.04
PE Ratio
0.00
EPS
-205.20
Earnings Announcement
12-Aug-2024
Previous Close
0.68
Open
0.67
Day's Range
0.6622 - 0.7155
Year Range
0.643 - 283.2
Trading Volume
2,673,445
1 Day Change
-1.07%
5 Day Change
-10.29%
1 Month Change
-55.15%
3 Month Change
-91.65%
6 Month Change
-93.53%
Ytd Change
-93.80%
1 Year Change
-99.76%
3 Year Change
-100.00%
5 Year Change
-100.00%
10 Year Change
-100.00%
Max Change
-100.00%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.